Fibrinopeptides

Fibrinopeptides are small peptide fragments released during the transformation of fibrinogen into fibrin by the enzyme thrombin. There are two main fibrinopeptides, fibrinopeptide A (FpA) and fibrinopeptide B (FpB), which are cleaved from the N-terminal regions of the Aα and Bβ chains of fibrinogen, respectively, as thrombin acts on the molecule.

The release of FpA and FpB marks an early step in clot formation. Their removal from fibrinogen allows fibrin monomers to polymerize into a fibrous clot. Because the peptides are small and soluble, they diffuse into the plasma and are detectable shortly after thrombin activation.

In clinical and research settings, measurements of FpA and FpB in plasma or serum serve as indicators of thrombin generation and coagulation activation. Immunoassays such as ELISA or radioimmunoassay are commonly used for this purpose. Elevated levels of fibrinopeptides can reflect increased thrombin activity and may be observed in conditions such as thrombosis, disseminated intravascular coagulation, or during certain therapeutic interventions that enhance coagulation.

Fibrinopeptides may also have biological effects beyond their role as markers. They have been reported to exhibit chemotactic activity for leukocytes and may contribute to inflammatory responses at sites of vascular injury. They are rapidly cleared from circulation and are degraded by proteolytic enzymes.

Overall, fibrinopeptides A and B are useful in understanding and assessing thrombin generation and coagulation activation in both clinical and research contexts.